Modified oligonucleotides as therapeutic and diagnostic agents
- 31 December 1995
- journal article
- research article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 6 (1), 12-19
- https://doi.org/10.1016/0958-1669(95)80003-4
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.Proceedings of the National Academy of Sciences, 1994
- Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)sAngewandte Chemie International Edition in English, 1994
- Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide againstrevfrom Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous InfusionAntisense Research and Development, 1994
- Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the MonkeyAntisense Research and Development, 1994
- Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early regionAntimicrobial Agents and Chemotherapy, 1993
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- The Functionalization of Oligonucleotides Via Phosphoramidite DerivativesTetrahedron, 1993
- In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital wartsAntimicrobial Agents and Chemotherapy, 1993
- Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I TrialAntisense Research and Development, 1993
- Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in MiceAntisense Research and Development, 1993